Coronary Heart Disease Statistics in US 2026 | Key Facts

What is Coronary Heart Disease in America 2026

Coronary heart disease (CHD) — also called coronary artery disease (CAD) — is the single most common and deadliest form of cardiovascular disease in the United States. It occurs when fatty deposits known as plaque build up inside the coronary arteries, the vessels responsible for delivering oxygen-rich blood to the heart muscle. Over time, this process — called atherosclerosis — narrows the arteries and restricts blood flow, which can trigger chest pain (angina), heart attacks (myocardial infarctions), dangerous arrhythmias, and sudden cardiac death. According to the Centers for Disease Control and Prevention (CDC), coronary heart disease has been the leading cause of death in the United States since 1921 — a grim record spanning more than 104 consecutive years. As of 2026, despite enormous progress in medicine and public health, CHD remains responsible for 38.2% of all cardiovascular deaths in the country, making it far and away the dominant killer within the already-massive burden of heart disease.

What gives coronary heart disease statistics in America 2026 particular urgency is the convergence of several deeply troubling trends happening simultaneously. The AHA 2026 Heart Disease and Stroke Statistics Update, published January 21, 2026, in Circulation, reveals that while the absolute number of CHD deaths declined slightly from 2022 to 2023 — a modest piece of good news — nearly half of all US adults now live with some form of cardiovascular disease, a rate still higher than pre-pandemic levels. At the same time, the JACC Cardiovascular Statistics 2026 report, published January 12, 2026, confirms that CAD prevalence has been climbing steadily since 2019 across nearly every demographic subgroup, while the three major upstream risk drivers — hypertension, diabetes, and obesity — are all getting worse, not better. For every American who reads this article, understanding these numbers in full is the first and most important step toward meaningful, life-saving action.

Interesting Key Facts About Coronary Heart Disease in the US 2026

Before the detailed statistics sections, here is a consolidated table of the most striking and verified facts about coronary heart disease in America, drawn exclusively from the most authoritative peer-reviewed and government sources available as of February 27, 2026.

Source: AHA 2026 Heart Disease and Stroke Statistics Update — Palaniappan LP et al., Circulation, January 21, 2026 (doi: 10.1161/CIR.0000000000001412); JACC Cardiovascular Statistics in the United States, 2026 — Wadhera RK et al., J Am Coll Cardiol., January 12, 2026 (doi: 10.1016/j.jacc.2025.12.027); CDC Heart Disease Facts, cdc.gov, updated October 2024; CDC NCHS Multiple Cause of Death 2023, CDC WONDER Database, accessed February 1, 2025; AHA 2026 At-a-Glance Fact Sheet, professional.heart.org, January 2026.

These facts collectively reflect a nation at a pivotal and precarious crossroads with its cardiovascular health. The slight decline in CHD deaths from 371,506 in 2022 to 349,470 in 2023 is genuinely welcome — it reflects the post-pandemic rebound in life expectancy and continued improvements in acute cardiac care. But that modest progress stands in stark contrast to a deeply troubling undercurrent: CAD prevalence has been rising since 2019, nearly half of all American adults already have some form of cardiovascular disease, and the foundational risk factors — particularly high blood pressure (47.3% of adults), diabetes (29.5 million diagnosed), and obesity (40.1%) — are all trending in the wrong direction. With only 1 in 2 CHD patients receiving optimal medical therapy and only 36.4% of adults carrying zero CVD risk factors, the prevention gap is as wide as ever. These numbers are not statistical abstractions — they represent real, preventable loss of life happening every single day across every state in the country.

Coronary Heart Disease Prevalence Statistics in the US 2026

Understanding how many Americans are currently living with coronary heart disease — and how those numbers are changing — is the essential starting point for any meaningful clinical or policy response to this epidemic.

Source: JACC Cardiovascular Statistics in the United States, 2026 — Wadhera RK et al., J Am Coll Cardiol., January 12, 2026; AHA 2026 Heart Disease and Stroke Statistics Update — Palaniappan LP et al., Circulation, January 21, 2026; CDC BRFSS 2022 dataset; CDC Heart Disease Facts, cdc.gov, October 2024.

The prevalence picture for coronary heart disease in the US 2026 is one of modest long-term progress being steadily unwound by modern lifestyle trends. The headline finding from JACC Stats 2026 is unambiguous: after two-plus decades of steady decline in CAD prevalence from 1990 through 2015, followed by a period of relative stability, rates have been climbing consistently since 2019 across almost all demographic subgroups. Men’s CAD prevalence jumped from 5.9% to 6.4% in just three years (2019–2022), while Asian adults — previously among the lowest-risk groups — saw their rate leap from 2.8% to 3.8%, a 36% relative increase that demands urgent attention and targeted outreach. The stark disparity between veterans (prevalence of 12.6%–13.4%) and non-veterans underscores the long-term cardiovascular toll of military service, while the powerful association between unemployment and CAD (rates up to 10.3% vs. only 1.9% for employed adults) confirms that cardiovascular disease cannot be understood or addressed without understanding the economic and social conditions in which it develops. With youth obesity now at 28.1% — up from 25.4% just a few years ago — the pipeline for the next generation of CHD patients is already filling.

Coronary Heart Disease Mortality Statistics in the US 2026

Mortality data — who is dying from CHD, at what rate, and whether that rate is improving — is the most direct and sobering measure of where this disease stands against all the resources society has devoted to fighting it.

Source: AHA 2026 Heart Disease and Stroke Statistics Update — Palaniappan LP et al., Circulation, January 21, 2026 (doi: 10.1161/CIR.0000000000001412); AHA 2026 At-a-Glance Fact Sheet, professional.heart.org, January 2026; CDC NCHS Multiple Cause of Death 2023, CDC WONDER Database, accessed February 1, 2025; JACC Cardiovascular Statistics in the United States, 2026.

The 2023 CHD mortality figures confirmed by the AHA’s 2026 Statistics Update carry genuinely mixed messages that deserve careful interpretation. The drop from 371,506 deaths in 2022 to 349,470 in 2023 — a reduction of roughly 22,000 lives — is meaningful and reflects the broader post-COVID-19 rebound in overall life expectancy now filtering through cardiovascular outcomes data. But 349,470 deaths from a single disease in a single year is still a staggering toll — equivalent to the entire population of a major American city — and CHD’s 38.2% share of all CVD deaths means it remains the dominant cardiovascular killer by a wide margin over stroke (17.8%), heart failure (9.8%), and hypertensive diseases (14.5%). The age-adjusted CVD death rate of 218.3 per 100,000 in 2023 is an improvement over 224.3 in 2022, and the long-term story of a ~50% reduction in CAD mortality between 2000 and 2020 is genuinely one of modern medicine’s significant achievements. However, the fact that 1 in 6 CVD deaths in 2023 was among adults younger than 65 signals a deeply troubling premature mortality burden driven by rising rates of obesity, diabetes, and hypertension appearing at earlier ages than in any previous generation.

Coronary Heart Disease by Race and Ethnicity in the US 2026

The racial and ethnic disparities embedded in coronary heart disease statistics represent one of the most persistent, urgent, and ethically significant findings across all major national cardiovascular surveillance reports.

Source: CDC Heart Disease Facts, cdc.gov, updated October 2024; AHA 2026 Heart Disease and Stroke Statistics Update — Palaniappan LP et al., Circulation, January 21, 2026; JACC Cardiovascular Statistics in the United States, 2026 — Wadhera RK et al., J Am Coll Cardiol., January 12, 2026.

The racial and ethnic data embedded in US coronary heart disease statistics 2026 reveals a healthcare system that is not serving all Americans equally — and has not for generations. Non-Hispanic Black adults carry the heaviest proportional burden of CVD deaths at 22.6% of all cardiovascular deaths in 2021, alongside a staggering ~59% CVD prevalence in NHANES 2017–2020 data, meaning more than half of all Black American adults were already living with some form of cardiovascular disease during that period. JACC Stats 2026 adds an equally troubling treatment gap dimension: non-Hispanic Black men are significantly less likely than White men to be on statin therapy following a cardiovascular event (adjusted prevalence ratio 0.81), and Mexican American and non-Mexican Hispanic women have some of the lowest statin adherence rates of any group — receiving guideline-recommended preventive therapy at barely half the rate of White women. These are not gaps in biological predisposition — they are gaps in access, prescribing patterns, trust, and structural equity within the US healthcare system. The alarming rise in Asian adults’ CAD rate from 2.8% to 3.8% — a nearly 36% relative jump in just a few years — combined with projections showing diabetes prevalence rising to 26.8% of US adults by 2050, predominantly in minority subgroups, means that today’s disparities will compound dramatically unless targeted action is taken now.

Heart Attack Statistics in the US 2026

Heart attacks (myocardial infarctions) are the most acute, dangerous, and visible manifestation of coronary heart disease in the US, and the frequency with which they strike Americans remains one of the most jarring statistics in the entire cardiovascular surveillance dataset.

Source: CDC Heart Disease Facts, cdc.gov, October 2024; AHA 2026 Heart Disease and Stroke Statistics Update — Palaniappan LP et al., Circulation, January 21, 2026; JACC Cardiovascular Statistics in the United States, 2026 — Wadhera RK et al., J Am Coll Cardiol., January 12, 2026; AHA 2026 Top Takeaways document, professional.heart.org.

The sheer volume of heart attacks in the United States — 805,000 per year, one every 40 seconds — demands to be taken seriously both as a public health emergency and as a deeply personal risk for millions of American families. The breakdown between 605,000 first heart attacks and 200,000 recurrent events highlights two entirely distinct prevention battles: stopping a first MI from ever occurring through primary prevention and lifestyle intervention, and ensuring that the people who have already survived one receive the optimal secondary prevention therapies that keep a second event from happening. The data confirming that only 1 in 2 CHD patients receives optimal medical therapy maps directly onto that 200,000 annual recurrent heart attack figure — representing preventable events in diagnosed patients who are not receiving guideline care. The emergency response data from 2024 adds another dimension to the tragedy: with only 42% bystander CPR rates and only 10.5% survival to hospital discharge for out-of-hospital cardiac arrests, the gap between what emergency response science makes possible and what actually happens in American communities is enormous and entirely closable with training and public investment. The rise in AMI hospitalizations among younger American adults since 2019 — at a time when this metric had been stable for nearly a decade — confirms that obesity and diabetes are compressing the disease timeline into younger and younger cohorts.

Coronary Heart Disease Risk Factors Statistics in the US 2026

The major modifiable risk factors for coronary heart disease are well established, evidence-based, and largely controllable — yet the data confirms that the United States is failing to control them at the population level.

Source: AHA 2026 Heart Disease and Stroke Statistics Update — Palaniappan LP et al., Circulation, January 21, 2026; JACC Cardiovascular Statistics in the United States, 2026 — Wadhera RK et al., J Am Coll Cardiol., January 12, 2026; CDC NCHS Data Brief No. 540, September 2025 (Prevalence of Cardiovascular Disease Risk Factors in Adults: United States, August 2021–August 2023).

The risk factor data for coronary heart disease in the US 2026 reads less like a progress report and more like a slow-motion emergency that has been building for years. The finding that only 36.4% of American adults carry zero major CVD risk factors means that roughly two-thirds of the entire adult population — well over 150 million people — already have one or more conditions actively driving them toward a future heart attack or CHD diagnosis. Hypertension, now affecting 125.9 million Americans — 47.3% of all adults — has seen its control rate actually decline from 54.1% in 2013–2014 to 48.3% by 2017–2020, a regression that occurred despite 15 years of available, affordable, and highly effective antihypertensive medications. The diabetes landscape is no less alarming: 29.5 million with diagnosed diabetes, 96 million with prediabetes, and only 43.5% of those being treated achieving adequate glycemic control — three compounding failures that together place an enormous additional CHD burden on the country year after year. The entirely new chapter on cardiovascular-kidney-metabolic (CKM) syndrome in the AHA 2026 Statistics Update — finding that 90% of US adults already have some level of CKM syndrome — offers perhaps the clearest lens of all on the scale of the underlying risk crisis that will drive coronary heart disease in America for decades to come unless prevention becomes the true national priority it has never yet fully been.

Coronary Heart Disease Economic Burden in the US 2026

The financial cost of coronary heart disease in the United States is enormous by any measure — affecting individual patients, employer productivity, insurance systems, and government healthcare programs alike.

Source: AHA 2026 Heart Disease and Stroke Statistics Update — Palaniappan LP et al., Circulation, January 21, 2026; AHA 2026 At-a-Glance Fact Sheet, professional.heart.org, January 2026; CDC Heart Disease Facts, cdc.gov, October 2024; NHLBI MEPS tabulation as cited in AHA 2025 and 2026 Statistical Summary Tables; CDC NCHS FastStats — Heart Disease, cdc.gov/nchs/fastats.

The $414.7 billion total annual cost of cardiovascular disease in the United States — encompassing direct healthcare spending and lost productivity — makes CHD not just a health crisis but one of the most significant drivers of economic drag across the entire national economy. The near-tripling of direct CVD costs from $103.5 billion in 1996–97 to $254.3 billion by 2019–20 demonstrates how two decades of modest mortality improvements have been more than offset by a growing burden of chronic illness requiring sustained medication, repeat hospitalizations, revascularization procedures, and long-term cardiac rehabilitation. The 13 million physician office visits per year for coronary atherosclerosis and ischemic heart disease alone — alongside the fact that 6.9% of all physician office visits carry a CAD history on the medical record — illustrates the enormous ongoing demand this single disease places on primary care and specialist infrastructure alike. Looking forward, with hypertension projected to reach 61% of US adults and diabetes projected to reach 26.8% by 2050, the cost trajectory for coronary heart disease in America is unmistakably upward unless prevention and control of these upstream risk factors become the true centerpiece of national health investment.

Coronary Heart Disease Treatment and Care Gaps in the US 2026

The distance between what evidence-based medicine can deliver for CHD patients and what they actually receive defines one of the most correctable failures in American healthcare — with profound implications for preventable death and disability.

Source: JACC Cardiovascular Statistics in the United States, 2026 — Wadhera RK et al., J Am Coll Cardiol., January 12, 2026 (doi: 10.1016/j.jacc.2025.12.027); AHA 2026 Heart Disease and Stroke Statistics Update — Palaniappan LP et al., Circulation, January 21, 2026; AHA 2026 Top Takeaways, professional.heart.org, January 2026; CDC Heart Disease Facts, cdc.gov, October 2024.

The coronary heart disease treatment gap data for the US in 2026 is arguably the most actionable body of statistics in this entire article — because every underperformance data point it reveals represents lives that could be saved today, without waiting for new scientific breakthroughs or drug discoveries. The anchor finding from JACC Cardiovascular Statistics 2026 that only 1 in 2 Americans with CHD receives optimal medical therapy is not an outlier finding — it is drawn from nationally representative NHANES surveys and means that millions of diagnosed CHD patients are not receiving the combination of statins, antihypertensives, antiplatelet agents, and lifestyle interventions that current guidelines unambiguously recommend. The statin data is particularly striking: even among adults aged 40–75 with a 10-year ASCVD risk of 7.5% or higher — a group for whom statin therapy carries a Class I guideline recommendation — only 19.1% are actually taking the drug. The racial and ethnic prescribing gap compounds this failure: high-risk Black and Hispanic adults are receiving statin therapy at roughly 60% of the rate of comparable White adults, directly contributing to the mortality disparities documented elsewhere in the data. The arrival of GLP-1 receptor agonists with demonstrated cardiovascular benefit in high-risk populations, currently used by only ~18% of Americans for any indication as of November 2025, represents perhaps the most significant underutilized opportunity in modern cardiovascular prevention — one that the healthcare system must urgently and equitably scale.

Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.